You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
復星醫藥(02196.HK)一季度扣非淨利潤同比增加21.73%至8.01億元

格隆匯4月26日丨復星醫藥(02196.HK)公吿,2022年第一季度,集團實現營業收入103.82億元,同比增長28.87%;實現歸屬於上市公司股東的扣除非經常性損益的淨利潤8.01億元,同比增加1.43億元,增長21.73%。但由於市場波動等因素,集團所持有的BNTX股票等金融資產於報吿期末的股價較2021年末下降,該等金融資產的公允價值變動損失致本集團報吿期內非經常性損益為-3.38億元,上年同期非經常性損益為1.89億元,同比減少5.27億元。由於非經常性損益同比減少的影響,報吿期內集團歸屬於上市公司股東的淨利潤為4.63億元,同比減少45.41%。

報吿期內,受益於復必泰(mRNA新冠疫苗)、漢曲優(注射用曲妥珠單抗)、蘇可欣(馬來酸阿伐曲泊帕片)、肝素系列製劑等產品的增長貢獻,集團營業收入以及歸屬於上市公司股東的扣除非經常性損益的淨利潤保持持續增長。

報吿期內,國內疫情有所反覆,集團積極響應各地疫情防控政策,採取應對措施,保障生產經營活動有序進行。同時,集團繼續推進創新產品、技術的開發落地,深耕海外市場,加速全球化進程。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account